Citigroup Cuts Teladoc Health (NYSE:TDOC) Price Target to $7.50

Teladoc Health (NYSE:TDOC) had its target price reduced by Citigroup from $11.00 to $7.50 in a research note released on Monday,Benzinga reports. They currently have a neutral rating on the health services provider’s stock.

Other research analysts have also recently issued research reports about the company. Bank of America boosted their price objective on Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Weiss Ratings upgraded Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Finally, Canaccord Genuity Group dropped their target price on Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Five equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $7.54.

Teladoc Health Stock Up 3.0%

Teladoc Health stock opened at $6.91 on Monday. Teladoc Health has a 52-week low of $4.40 and a 52-week high of $9.89. The firm has a fifty day moving average of $8.22 and a 200-day moving average of $6.54. The firm has a market capitalization of $1.26 billion, a P/E ratio of -6.98 and a beta of 2.12.

Teladoc Health (NYSE:TDOC) last issued its earnings results on Wednesday, July 29th. The health services provider reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.04. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The business had revenue of $606.93 million for the quarter, compared to the consensus estimate of $615.44 million. During the same quarter last year, the firm posted ($0.19) EPS. The business’s revenue for the quarter was down 4.0% compared to the same quarter last year. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. On average, research analysts expect that Teladoc Health will post -0.89 EPS for the current fiscal year.

Insider Activity

In other news, insider Adam C. Vandervoort sold 7,906 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $60,322.78. Following the completion of the sale, the insider directly owned 110,261 shares in the company, valued at $841,291.43. This trade represents a 6.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Fernando M. Rodrigues sold 5,677 shares of Teladoc Health stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $43,315.51. Following the sale, the insider directly owned 9,572 shares in the company, valued at approximately $73,034.36. The trade was a 37.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 39,195 shares of company stock valued at $299,058 in the last 90 days. Company insiders own 0.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Jupiter Asset Management Ltd. increased its holdings in Teladoc Health by 293.9% during the 4th quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock worth $27,021,000 after purchasing an additional 2,880,008 shares during the last quarter. Quantinno Capital Management LP raised its position in shares of Teladoc Health by 128.0% in the 1st quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider’s stock valued at $14,287,000 after purchasing an additional 1,471,631 shares in the last quarter. Pale Fire Capital SE boosted its stake in shares of Teladoc Health by 74.8% during the 1st quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider’s stock valued at $18,522,000 after buying an additional 1,454,288 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Teladoc Health by 23.8% during the third quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock worth $53,260,000 after buying an additional 1,325,106 shares in the last quarter. Finally, Trexquant Investment LP acquired a new stake in shares of Teladoc Health during the fourth quarter worth approximately $9,156,000. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.